LAS VEGAS, Oct. 15 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.
The entire interview is available at http://gaskinsco.com/cbai-10-14-09.mp3
In the interview Mr. Schissler said: -- The Company is now operating day to day operations from its headquarters at the 17,000 square foot facility at 1857 Helm Drive, near the Las Vegas airport. -- The purchase of laboratory equipment has begun and is in process of being set up and readied for validation. The remaining equipment is actively being sourced and expected to be completed by November. The Company expects the first of its cryogenic tanks for storage to begin arriving in December and anticipates a final count of 20-25 tanks to be installed and storing umbilical cord blood stem cells by the end of January. The facility will perhaps be the largest cryogenic storage lab in the U.S. -- The Company expects to hold a grand opening ceremony at the facility, with the date to be announced.
The interview also includes details about the Company's future business strategies and possible business opportunities, which are being evaluated. Mr. Schissler said the new facility will significantly reduce storage costs for Cord Blood America and will allow it to do research and development and to process and store multiple stem cell lines or other medical products.
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as anticipate,'' believe,'' expect,'' future,'' intend,'' plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.
Web Site: http://www.cordblood-america.com/
